]> 2026-04-12T03:51:31-07:00 DNX-2401 adenovirus 0 en Not specified 2025-01-18T08:29:09Z 2460693.8535764 DNX-2401 adenovirus 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO\ntrial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.\nPreliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented\nat the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma\npatients had been treated, with no adverse events attributable to the virus being reported.\n3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,\nand 29 months so far. These three complete responders had vigorous immune responses,\nwith 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance\nfor type-1 anti-tumor immune responses."] DNX-2401 adenovirus# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name